Last reviewed · How we verify
Cantil (MEPENZOLATE)
Cantil (mepenzolate) is a small molecule anticholinergic medication originally developed by Sanofi Aventis US and currently owned by the same company. It targets the muscarinic acetylcholine receptor M2 to treat gastric and peptic ulcers. Approved by the FDA in 1956, Cantil is off-patent and has no active Orange Book patents, indicating it is available as a generic medication. However, there are currently no generic manufacturers listed. As an anticholinergic, Cantil works by reducing stomach acid production.
At a glance
| Generic name | MEPENZOLATE |
|---|---|
| Sponsor | Sanofi |
| Drug class | Anticholinergic |
| Target | Muscarinic acetylcholine receptor M2 |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
| First approval | 1956 |
Approved indications
- Gastric ulcer
- Peptic ulcer
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cantil CI brief — competitive landscape report
- Cantil updates RSS · CI watch RSS
- Sanofi portfolio CI